Furthermore, in HER2-positive ovarian cancer xenograft models, 227Th-trastuzumab delayed tumor growth and was associated with survival benefit vs. unlabeled trastuzumab (58, 59) or 177Lu-trastuzumab (at the same absorbed radiation dose to tumor) (59). This evidence concerns the gene ERBB2 and ovarian carcinoma.